Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SOLTI Breast Cancer Research Group
With
Eisai Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent, specifically highlighting the molecular characterization of tumor and genomic samples
Age ≥18 years
Histologically confirmed invasive breast carcinoma, with all of the following characteristics:
* Primary tumor ≥2cm in largest diameter (cT1-3)
* cN0-1
* No evidence of distant metastasis (M0)
Breast cancer (BC) eligible for primary surgery
Available pre-treatment core (Tru-cut) biopsy or possibility of performing one
HER2-negative BC (as per local assessment), defined as either of the following:
* 0-1+ expression by IHC
* 2+ expression by IHC and in situ hybridization (FISH/CISH) without HER2 gene amplification (\<4 HER2 gene copies per nucleus, or a FISH ratio \[HER2 gene copies to Cr17 signals\] of \<1.8)
* Is situ hybridization (FISH/CISH) without HER2 gene amplification, independently of IHC
Known hormone receptor (ER/PgR) status (as per local assessment) or the possibility of performing the tests
Known percentage of hormone receptor (ER/PgR) and Ki67-positive tumor cells (as per local assessment), or possibility of performing the tests
In the case of a multifocal tumor, the largest lesion must be ≥2 cm and designated the "target" lesion for all subsequent tumor evaluations and HER2-negative status must be documented in all the tumor foci
ECOG performance status of 0 or 1
Laboratory values as follows:
* Absolute neutrophil count (ANC) ≥1.5 x 109/L
* Platelets count ≥100 x 109/L
* Hemoglobin ≥9 g/dL
* Serum bilirubin ≤1.5 time the upper limit of normal (ULN)
* Alanine aminotransferase and aspartate aminotransferase (AST) ≤2.5 x ULN
Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Ability and willingness to comply with study visits, treatment, testing, and to comply with the protocol
Availability of genomic DNA (via whole blood)
You may not be if
Any prior treatment for primary invasive BC
Metastatic, locally advanced or inflammatory (i.e., Stage III-IV) BC
Bilateral invasive BC
Multicentric BC, defined as the presence of two or more foci of cancer in different quadrants of the same breast
Concomitant use of inhibitors of hepatic transport proteins such as organic anion-transporting proteins, P-glycoprotein, multidrug resistant proteins etc
Major medical conditions that might affect study participation (e.g., uncontrolled seizure disorder, uncontrolled pulmonary, renal or hepatic dysfunction, or uncontrolled infection)
Other primary malignant tumors within the previous 5 years, except for adequately controlled limited basal cell carcinoma of the skin or carcinoma in situ of the cervix
Known human immunodeficiency virus(HIV) infection or other active or serious infection requiring IV antibiotics at randomization
Pregnancy or breastfeeding women
Women of childbearing potential(\<2 years after the last menstruation) not using effective, non-hormonal means of contraception during the study and for a period of 6 months following the last administration of study drug
Administration of any live virus vaccine within 8 weeks preceding study entry
Use of any investigational agent within 30 days of administration of the first dose of study drug or concurrent treatment on another clinical study
Requirement for radiation therapy concurrent with study anticancer treatment
Known hypersensitivity to any of the study drugs or excipients
Inability or unwillingness to abide by the study protocol or cooperate fully with the investigator or designee
Clareo Health | Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer
